ESMO posted on their LinkedIn page:
“ESMOBreast24: Let your research findings stimulate discussions and help us drive progress in the Breast Cancer field. Submit your abstract by 13 February.
Join us for the latest updates on:
new strategies for luminal, HER2positive, HER2-low and triple-negative breast cancer
novel antibody-drug conjugates for breast cancer.”
For submissions click here.
Source: ESMO/LinkedIn